MWNA
TVTX icon

Marshall Wace North America’s Travere Therapeutics TVTX Stock Holding History

Marshall Wace North America’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$603K Buy
+24,832
New +$456K ﹤0.01% 1070
2021
Q2 		– Sell
-58,152
Closed -$1.45M – 1785
2021
Q1 		$1.45M Buy
+58,152
New +$1.61M 0.01% 913
2019
Q2 		– Sell
-1,062
Closed -$24K – 1617
2019
Q1 		$24K Buy
+1,062
New +$23.5K ﹤0.01% 1366

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Marshall Wace North America's TVTX Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Travere Therapeutics (TVTX) in Q3 2021: 24,832 shares worth $603K. The stake represents ﹤0.01% of the portfolio and ranks #1070 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in TVTX as recently as Q1 2021.

Marshall Wace North America first reported a position in TVTX in Q1 2019 and has held it in 3 quarters since. The position peaked at $1.45M in Q1 2021. 148 funds tracked by Wall St. Rank hold TVTX as of Q3 2021.

  • Marshall Wace North America held 24,832 shares of Travere Therapeutics worth $603K as of Q3 2021.
  • Travere Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Travere Therapeutics made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1070 holding.
  • Marshall Wace North America first reported a position in Travere Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Marshall Wace North America's Travere Therapeutics position peaked at $1.45M in Q1 2021.
  • 148 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.